Vivanza Biosciences Limited

BSE: VIVANZA530057ISIN INE984E01035

Healthcare
Pharmaceuticals

Share price

₹1.36-0.04 (-2.86%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2.72
52W low: ₹1.30
Off 52W high: -50.00%
1M return: -19.53%
3M return: -28.42%
6M return: -32.00%
1Y return: -30.96%
20D avg volume: 19,970
50 DMA: ₹1.70
200 DMA: ₹1.88

Key ratios Consolidated

Market cap: ₹5.44 Cr
Current price: ₹1.36
52W high / low: ₹2.72 / ₹1.30
Face value: ₹1.00
P/E: 11.98
P/B: 1.25
EPS (TTM): ₹0.11
Book value / share: ₹1.09
ROE: —
ROCE: 15.60%
Operating margin: —
Net margin: —
Debt / equity: 2.34
Net debt: ₹10.12 Cr
Interest cover: 2.93
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 27.6 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	9.29	6.36	45.25	55.36	8.94	0.48	1.50	3.00	2.44	—
	0.37	0.01	0.08	0.01	0.02	0.05	0.01	0.00	0.00	—
	9.66	6.37	45.33	55.37	8.96	0.53	1.51	3.00	2.44	—
	9.48	6.67	45.13	54.80	8.87	1.52	1.47	2.99	2.18	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	9.47	5.96	44.15	55.99	9.61	0.48	1.47	2.82	2.30	—
	0.10	0.07	0.04	0.25	0.14	0.15	0.13	0.14	0.15	—
	0.11	0.07	0.09	0.05	0.08	0.08	0.09	0.09	0.09	—
	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.05	0.01	0.09	0.07	0.10	0.11	0.14	0.04	0.10	—
	0.18	-0.30	0.20	0.56	0.09	-0.99	0.04	0.02	0.27	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.18	-0.30	0.20	0.56	0.09	-0.99	0.04	0.02	0.27	—
	0.04	0.15	0.00	0.00	0.00	0.01	0.00	0.00	0.00	—
	0.15	-0.45	0.20	0.56	0.09	-1.00	0.04	0.02	0.27	—
	0.04	-0.11	0.05	0.14	0.02	-0.25	0.01	—	0.07	—
Key metrics
	0.30	-0.22	0.29	0.61	0.17	-0.91	0.13	0.11	0.36	—
	3.20%	-3.50%	0.60%	1.10%	1.90%	-189.60%	8.70%	3.70%	14.80%	—
	1.60%	-7.10%	0.40%	1.00%	1.00%	-208.30%	2.70%	0.70%	11.10%	—
	—	-4.40%	—	7.40%	—	-12.50%	—	—	—	—
	3.90%	1,225.00%	2,916.70%	1,745.30%	266.40%	—	—	—	—	—
	66.70%	55.00%	400.00%	2,700.00%	-66.70%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	116.26	115.91	7.42	—
	0.47	0.11	0.06	—
	116.73	116.02	7.49	—
	116.08	115.48	8.15	—
	0.00	0.00	0.00	—
	115.57	115.71	7.08	—
	0.46	0.49	0.58	—
	0.32	0.28	0.35	—
	0.02	0.02	0.01	—
	0.22	0.26	0.39	—
	0.64	0.54	-0.67	—
	0.00	0.00	0.00	—
	0.64	0.54	-0.67	—
	0.19	0.15	0.01	—
	0.46	0.39	-0.67	—
	0.12	0.10	-0.17	—
Key metrics
	0.98	0.84	-0.31	—
	0.84%	0.70%	-4.20%	—
	0.40%	0.30%	-9.00%	—
	—	15.60%	-4.40%	—
	735.20%	1,462.10%	—	—
	—	158.20%	—	—
	—	-1.38	-2.51	—
	—	-3.23	3.73	—
	—	2.34	2.18	—
	—	10.12	8.53	—
	—	27.6	378.8	—
Balance sheet
	—	22.09	16.45	—
	—	19.05	12.38	—
	—	0.07	0.12	—
	—	12.38	8.06	—
	—	3.55	2.26	—
	—	0.00	0.00	—
	—	0.80	0.70	—
	—	7.19	2.62	—
	—	16.85	9.15	—
	—	10.19	8.65	—
	—	9.31	5.32	—
	—	0.88	3.33	—
	—	4.36	3.96	—
Cash flow
	—	-1.26	-2.50	—
	—	-0.05	-0.01	—
	—	1.26	2.46	—
	—	0.12	0.01	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	9.14	5.75	44.93	53.73	7.82	0.17	0.76	1.58	0.43	—
	0.37	0.01	0.08	0.01	0.02	0.02	0.01	0.00	0.00	—
	9.51	5.75	45.01	53.74	7.84	0.19	0.77	1.58	0.43	—
	9.33	5.88	44.85	53.28	7.82	1.15	0.73	1.58	0.20	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	9.33	5.34	43.87	55.16	7.71	0.17	0.75	1.42	0.32	—
	0.10	0.04	0.04	0.16	0.09	0.11	0.07	0.09	0.09	—
	0.11	0.07	0.09	0.05	0.08	0.08	0.09	0.09	0.09	—
	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.05	0.00	0.09	0.04	0.09	0.09	0.11	0.02	0.10	—
	0.18	-0.12	0.16	0.46	0.02	-0.96	0.04	0.01	0.23	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.18	-0.12	0.16	0.46	0.02	-0.96	0.04	0.01	0.23	—
	0.04	0.14	0.00	0.00	0.00	0.00	—	—	—	—
	0.15	-0.27	0.16	0.46	0.02	-0.97	0.04	0.01	0.23	—
	0.04	-0.07	0.04	0.12	0.01	-0.24	0.01	—	0.06	—
Key metrics
	0.30	-0.04	0.25	0.51	0.10	-0.88	0.13	0.10	0.32	—
	3.30%	-0.70%	0.60%	0.90%	1.30%	-517.60%	17.10%	6.30%	74.40%	—
	1.60%	-4.70%	0.40%	0.90%	0.30%	-570.60%	5.30%	0.60%	53.50%	—
	—	-0.90%	—	9.70%	—	-18.40%	—	—	—	—
	16.90%	3,282.40%	5,811.80%	3,300.60%	1,718.60%	—	—	—	—	—
	650.00%	72.20%	300.00%	4,500.00%	-91.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	113.55	112.23	2.94	—
	0.47	0.11	0.04	—
	114.01	112.34	2.98	—
	113.34	111.82	3.67	—
	0.00	0.00	0.00	—
	113.70	112.07	2.67	—
	0.34	0.33	0.37	—
	0.32	0.28	0.35	—
	0.02	0.02	0.01	—
	0.18	0.22	0.31	—
	0.68	0.52	-0.69	—
	0.00	0.00	0.00	—
	0.68	0.52	-0.69	—
	0.18	0.14	0.00	—
	0.50	0.38	-0.70	—
	0.13	0.09	-0.17	—
Key metrics
	1.02	0.82	-0.33	—
	0.90%	0.70%	-11.20%	—
	0.44%	0.30%	-23.80%	—
	—	15.20%	-7.10%	—
	999.23%	3,717.30%	—	—
	—	154.30%	—	—
	—	-1.33	-2.47	—
	—	-3.18	3.53	—
	—	1.70	1.52	—
	—	7.48	6.05	—
	—	24.6	746.1	—
Balance sheet
	—	18.23	13.91	—
	—	15.59	11.38	—
	—	0.02	0.05	—
	—	10.66	7.39	—
	—	2.95	1.84	—
	—	—	0.30	—
	—	0.12	0.02	—
	—	6.07	3.22	—
	—	12.95	9.12	—
	—	7.50	6.10	—
	—	6.62	5.32	—
	—	0.88	0.78	—
	—	4.40	4.02	—
Cash flow
	—	-1.21	-2.47	—
	—	0.05	-0.01	—
	—	1.13	2.44	—
	—	0.12	0.00	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +999.23%
Profit YoY (TTM): +155.56%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +735.20%
Profit YoY (TTM): +154.12%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 20.02%

Quarter	September 2026	June 2026
Promoter %	20.02%	20.02%

Holder	Type	Holding	Previous	Change
PARTH HEMANT PARIKH	Promoter	19.77%	19.77%	0.00%
RAVINDER SINGH	Public	1.75%	1.70%	+0.05%
PRASHANT TYAGI	Public	1.51%	1.51%	0.00%
MANU NARANG	Public	1.43%	1.44%	-0.01%
HEMANT AMRISH PARIKH	Promoter	0.25%	0.25%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Vivanza Biosciences Limited	5	1.36	11.98	15.60%	+735.20% TTM	+154.12% TTM	-30.96%

Filings & corporate actions

Recent announcements

Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Unaudited Standalone and ....3 Nov 2026 · Company Update / Board Meeting Rescheduled
Non-applicability of Reg 23 (9) of SEBI (LODR) Regulation, 2015 for the Quarter on 30th September, 2026.29 Oct 2026 · Company Update / General
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve unaudited standalone and ....28 Oct 2026 · Board Meeting / Board Meeting
Non applicability of the statements of Variation and Deviation under regulation 32 of SEBI LODR Regulation, 2015 as Company has not raised any further funds, hence statements of Deviation ....8 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Compliance certificate under reg. 74(5) of SEBI (DP) Regulation 2018, received from Purva Share Registry (I) Pvt Ltd and Share Transfer Agent (RTA) of the company for the Quarter ended ....2 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter and half year ending 30th September, 2026.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Voting Result for the 44th Annual General Meeting of the Company12 Sep 2026 · AGM/EGM / AGM
Revised Outcome of the 44th Annual General Meeting of the Vivanza Biosciences Limited12 Sep 2026 · AGM/EGM / AGM
Outcome of the 44th Annual General Meeting of the Members of the Vivanza Biosciences Limited.11 Sep 2026 · AGM/EGM / AGM
Please find enclosed newspaper advertisement w.r.t Notice of 44th AGM of the Company and e-voting information.20 Aug 2026 · Company Update / General
Annual Report for the Financial Year 2025-2026 of the Company.19 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-2619 Aug 2026 · AGM/EGM / AGM
The Board of Directors of the Company at its meeting held on Monday, August 17, 2026, at the Registered Office, inter alia, considered and approved: 1. Director's Report, Secretarial Audit ....17 Aug 2026 · Board Meeting / Outcome of Board Meeting
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve 1) To consider and approve ....12 Aug 2026 · Board Meeting / Board Meeting
Pursuant to Regulation 32 of the SEBI(LODR) Regulation, 2015 Read with SEBI circular dated 24th December, 2019 regarding the submission of the statement of deviation or variation from the ....8 Aug 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
in the terms of Regulation 47 of the SEBI(LODR) Regulation, 2015 Please find the copy of the Newspaper in the English and vernacular Language of the State, wherein the Unaudited Standalone ....8 Aug 2026 · Company Update / Newspaper Publication
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .7 Aug 2026 · Result / Financial Results
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .7 Aug 2026 · Result / Financial Results
Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th ....7 Aug 2026 · Board Meeting / Outcome of Board Meeting
The Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026 The Board Meeting to be held on 01/08/2026 has been revised to 07/08/202631 Jul 2026 · Company Update / Board Meeting Rescheduled
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve 1. Unaudited Standalone ....28 Jul 2026 · Board Meeting / Board Meeting
we hereby declared that statutory auditor of the company M/s Shivam Soni & co, Chartered Accountant (FRN: 152477W) have issued an Audit Report with unmodified opinion on the Audited Financial ....14 Jul 2026 · Company Update / General
pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 appointmnet of Mr. Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer has been approved with effect from ....9 Jul 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Pursuant to Regulation 29 and other applicable provisions of the SEBI (LODR) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of the Company was held on ....9 Jul 2026 · Others / Outcome without intimation
Certificate under Regulation 47(5) of the SEBI ( Depository and Participant) Regulations, 2018, received from Purva Share Registry (I) Pvt Ltd and the share transfer agent (RTA) of the ....7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Execution of Strategic Corporation, Investment & Technology Transfer Agreement29 Jun 2026 · Company Update / Memorandum of Understanding /Agreements
Intimation of Closure of Trading Window for the Quarter ended on 30th June 202626 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Reg 29 and other applicable provisions of SEBI LODR Reg, 2015 this is to inform you that a meeting of the Board of Directors of the Company held on 18th June 2026 has considered ....18 Jun 2026 · Company Update / Change in Management
1.The Board of Directors of the Company, at its meeting held today, has considered and approved the following transactions. The meeting of the Board of Directors of the Company commenced ....18 Jun 2026 · Board Meeting / Outcome of Board Meeting
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 ,inter alia, to consider and approve 1.To authorise Mr. Sarang ....15 Jun 2026 · Board Meeting / Board Meeting
In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed copy of newspaper advertisement published in English daily ....9 May 2026 · Company Update / Newspaper Publication
This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations, 2015, Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations, ....7 May 2026 · Company Update / General
Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2026, Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS, Reconstitution of ....7 May 2026 · Result / Financial Results
Consideration of Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Audit Report of the Company for the Quarter and Year ended ....7 May 2026 · Board Meeting / Outcome of Board Meeting
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 ,inter alia, to consider and approve This is in continuation ....4 May 2026 · Company Update / Board Meeting Rescheduled
Intimation Regarding Resignation of Company Secretary & Compliance Officer pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015.30 Apr 2026 · Company Update / Change in Management
Intimation regarding Resignation of Company Secretary & Compliance Officer pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015.30 Apr 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 ,inter alia, to consider and approve Vivanza Biosciences Limited ....28 Apr 2026 · Board Meeting / Board Meeting
Non-Applicability of Regulation 24A of SEBI(LODR) Regulations, 201515 Apr 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015, attaching herewith Non-Applicability of Statement of Deviation.14 Apr 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation

Board meetings

6 Nov 2026 Board Meeting - Financial Results
3 Nov 2026 Board Meeting - Financial Results
7 Aug 2026 Board Meeting - Financial Results
1 Aug 2026 Board Meeting - Financial Results